SCHEMBL16631826

SCHEMBL16631826

Cc1[nH]c(=O)cc(F)c1[C@@H]1O[C@H](CO)C(O)[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYNJ2 O15056 1/20 0.46
KDM4E B2RXH2 4/20 0.40
SLC5A2 P31639 8/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
APEX1 P27695 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP3A4 P08684 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MMP14 P50281 1/20 0.39
MEN1 O00255 1/20 0.39
PTPN1 P18031 1/20 0.39
MAPK1 P28482 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MGAM O43451 1/20 0.39
GUSB P08236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631251 0.90 CDA (0.37) SYNJ2KDM4ESLC5A2ALDH1A1LMNA
SCHEMBL16631817 0.87 TNF (0.36) SYNJ2SLC5A2ALDH1A1LMNATSHR
SCHEMBL16631823 0.86 SYNJ2 (0.42) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1
SCHEMBL16631255 0.82 SYNJ2 (0.39) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1
SCHEMBL16631241 0.81 SYNJ2 (0.38) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1
SCHEMBL16631837 0.77 SYNJ2 (0.41) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1
SCHEMBL18079928 0.77 P2RY2 (0.54)
SCHEMBL16631249 0.76 CDA (0.38) SYNJ2KDM4ESLC5A2CYP3A4MAPT
SCHEMBL18158986 0.75 SYNJ2 (0.43) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1
SCHEMBL15810658 0.75 SYNJ2 (0.43) SYNJ2KDM4ESLC5A2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SYNJ2 642/4885KDM4E 4689/4885SLC5A2 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.